161 related articles for article (PubMed ID: 36876171)
1. The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.
Emirzeoglu L; Arici S; Sahin AB; Ocak B; Ak N; Ay S; Mammadov E; Turna H; Bilici A
Breast Care (Basel); 2023 Feb; 18(1):42-48. PubMed ID: 36876171
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer.
Arici S; Sengiz Erhan S; Geredeli C; Cekin R; Sakin A; Cihan S
Oncol Res Treat; 2020; 43(9):435-440. PubMed ID: 32570261
[TBL] [Abstract][Full Text] [Related]
3. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
[TBL] [Abstract][Full Text] [Related]
7. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Agrawal S; Banswal L; Saha A; Arun I; Datta SS; Chatterjee S; Ahmed R
Indian J Surg Oncol; 2016 Dec; 7(4):397-406. PubMed ID: 27872526
[TBL] [Abstract][Full Text] [Related]
8. Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response.
Lee HC; Ko H; Seol H; Noh DY; Han W; Kim TY; Im SA; Park IA
J Breast Cancer; 2013 Dec; 16(4):395-403. PubMed ID: 24454461
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Chatterjee S; Saha A; Arun I; Nayak SS; Sinha S; Agrawal S; Parihar M; Ahmed R
Breast Cancer (Dove Med Press); 2015; 7():381-8. PubMed ID: 26677343
[TBL] [Abstract][Full Text] [Related]
11. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study.
Tang L; Li Z; Jiang L; Shu X; Xu Y; Liu S
Front Oncol; 2022; 12():999716. PubMed ID: 36605428
[TBL] [Abstract][Full Text] [Related]
12. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
[TBL] [Abstract][Full Text] [Related]
13. Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: A single-institution experience.
Joshi S; Chougle Q; Noronha J; Hawaldar R; Nair N; Vanmali V; Parmar V; Thakkar P; Chitkara G; Shet T; Badwe RA
Indian J Cancer; 2023 Feb; ():. PubMed ID: 36861728
[TBL] [Abstract][Full Text] [Related]
14. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer.
Qian XL; Xia XQ; Li YQ; Jia YM; Sun YY; Song YM; Xue HQ; Hao YF; Wang J; Wang XZ; Liu CY; Zhang XM; Zhang LN; Guo XJ
Sci Rep; 2023 Jun; 13(1):9256. PubMed ID: 37286786
[TBL] [Abstract][Full Text] [Related]
15. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
18. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy.
Değerli E; Şentürk Öztaş N; Alkan G; Bedir Ş; Derin S; Valıkhanova N; Saraç B; Kacar E; Demirci NS; Demirelli HF; Turna H
J Chemother; 2023 Feb; 35(1):29-38. PubMed ID: 35220928
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.
Ruff P; Cubasch H; Joffe M; Rosenbaum E; Murugan N; Tsai MC; Ayeni O; Crew KD; Jacobson JS; Neugut AI
Cancer Manag Res; 2018; 10():279-286. PubMed ID: 29467582
[TBL] [Abstract][Full Text] [Related]
20. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu W; Jiang Y; Xu L; Li C; Wang J; Liu Z; Xue D; Gu Y; Zhong Z; He S; Wang S; Zhou W; Pan H
Jpn J Clin Oncol; 2023 Jun; 53(6):463-471. PubMed ID: 36757139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
